{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:09:23Z","timestamp":1770739763402,"version":"3.49.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/mjt.0b013e31825a3616","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T16:00:51Z","timestamp":1347552051000},"page":"151-153","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Cilostazol in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention"],"prefix":"10.1097","volume":"20","author":[{"given":"Taohong","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huili","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210202","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.104.530097","article-title":". Coronary stent restenosis in patients treated with cilostazol.","volume":"112","author":"Douglas","year":"2005","journal-title":"Circulation"},{"key":"R2-5-20210202","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/01.ATV.18.12.1942","article-title":". Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.","volume":"18","author":"Elam","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R3-5-20210202","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1540-8183.2006.00181.x","article-title":"Aspirin and clopidogrel resistance: consideration and management.","volume":"19","author":"Gurbel","year":"2006","journal-title":"J Interv Cardiol"},{"key":"R4-5-20210202","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.0000161383.06692.D4","article-title":". Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the armyda-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study.","volume":"111","author":"Patti","year":"2005","journal-title":"Circulation"},{"key":"R5-5-20210202","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":". Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"R6-5-20210202","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","article-title":". A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.","volume":"28","author":"von Beckerath","year":"2007","journal-title":"Eur Heart J"},{"key":"R7-5-20210202","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s001250100593","article-title":". Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.","volume":"44","author":"Aoki","year":"2001","journal-title":"Diabetologia"},{"key":"R8-5-20210202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0021-9150(98)00147-6","article-title":". Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.","volume":"142","author":"Ishizaka","year":"1999","journal-title":"Atherosclerosis"},{"key":"R9-5-20210202","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1253\/circj.71.1867","article-title":". Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.","volume":"71","author":"Kim","year":"2007","journal-title":"Circ J"},{"key":"R10-5-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0049-3848(99)00109-7","article-title":". Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.","volume":"96","author":"Kohda","year":"1999","journal-title":"Thromb Res"},{"key":"R11-5-20210202","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jacc.2005.07.048","article-title":". Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis.","volume":"46","author":"Lee","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R12-5-20210202","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","article-title":". Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (optimus) study.","volume":"115","author":"Angiolillo","year":"2007","journal-title":"Circulation"},{"key":"R13-5-20210202","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/01.fjc.0000167012.82930.8f","article-title":". A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.","volume":"46","author":"Ge","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"R14-5-20210202","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0091270002042012002","article-title":"Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.","volume":"42","author":"Grouse","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R15-5-20210202","first-page":"195","article-title":". Matrix metalloproteinase-1 gene -519ag polymorphism and the risk of coronary heart disease in northern chinese han population in Chinese.","volume":"36","author":"Han","year":"2008","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201303000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:42:57Z","timestamp":1618036977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201303000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31825a3616","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}